Allergan Aesthetics, an AbbVie company, has reported positive patient-reported outcomes from two Phase 4 studies evaluating aesthetic treatments in adults taking GLP-1 medications. The findings were presented at the 2026 American Society for Dermatologic Surgery Annual Meeting.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
The HARMONY IN DIVERSITY study assessed a combined regimen of hyaluronic acid injectables, onabotulinumtoxinA and skincare in 30 participants. At 30 days, patients reported a mean 42.4-point improvement in satisfaction with facial appearance, alongside improvements in skin quality and psychological and social function.
Interim results from the HALO study, which is evaluating HA injectables in adults using GLP-1 medications, showed a mean 39.6-point improvement in facial appearance satisfaction among 25 participants at three months. Additionally, 95.7% were satisfied or very satisfied that they still looked like themselves, while 82.6% reported satisfaction with the naturalness of their appearance.
Most treatment-related adverse events across both studies were mild. The findings add to research into aesthetic treatment approaches for patients experiencing facial changes during GLP-1 therapy, although the small study populations and interim nature of the HALO results warrant further investigation.
Read the full story here.
